EP1670473A1 - Substituted quinolines as protein tyrosine kinase enzyme inhibitors - Google Patents

Substituted quinolines as protein tyrosine kinase enzyme inhibitors

Info

Publication number
EP1670473A1
EP1670473A1 EP03818857A EP03818857A EP1670473A1 EP 1670473 A1 EP1670473 A1 EP 1670473A1 EP 03818857 A EP03818857 A EP 03818857A EP 03818857 A EP03818857 A EP 03818857A EP 1670473 A1 EP1670473 A1 EP 1670473A1
Authority
EP
European Patent Office
Prior art keywords
cyano
chloro
butenamide
quinolinyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03818857A
Other languages
German (de)
French (fr)
Inventor
Allan Wissner
Sridhar Krishna Rabindran
Hwei-Ru Tsou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34435322&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1670473(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of EP1670473A1 publication Critical patent/EP1670473A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • This invention relates to certain substituted 3-cyano quinoline compounds as well as the pharmaceutically acceptable salts thereof.
  • the compounds of the present invention inhibit the HER-2 and epidermal growth factor receptor (EGFR) enzyme thereby inhibiting the abnormal growth of certain cell types.
  • the compounds of this invention are anti-cancer agents and are useful for the treatment of cancer in mammals.
  • This invention also relates to the use of 3-cyano quinolines in the treatment of cancer and the pharmaceutical preparations containing them.
  • Protein tyrosine kinases are a class of enzymes that catalyze the transfer of a phosphate group from ATP to a tyrosine residue located on a protein substrate. Protein tyrosine kinases clearly play a role in normal cell growth.
  • the growth factor receptor kinases and their proto-oncogenes that have been identified and which are targets of the compounds of this invention are the epidermal growth factor receptor kinase (EGF-R kinase, the protein product of the erbB oncogene), and the product produced by the erbB-2 (also referred to as the neu or5 HER-2) oncogene.
  • EGF-R kinase epidermal growth factor receptor kinase
  • erbB-2 also referred to as the neu or5 HER-2
  • an inhibitor of this event a protein tyrosine kinase inhibitor, will have therapeutic value for the treatment of cancer and other diseases characterized by uncontrolled or abnormal cell growth.
  • EGF-R kinase has been associated with epidermoid tumors [Reiss, M., er a/., Cancer Res., 51, 6254 (1991)], breast tumors [Macias, A., et. al., Anticancer Res., 7, 459 (1987)], and tumors involving other major organs [Gullick, W. J., Brit. Med. Bui/., 47, 87 (1991)]. Because of the importance of the role played by deregulated receptor kinases in the pathogenesis of cancer, many recent studies have dealt with the development of specific PTK inhibitors as potential anti- cancer therapeutic agents [some recent reviews: Burke. T.
  • the compounds of this invention inhibit the kinase activity of EGF-R and are therefore useful for treating certain disease states, such as cancer, that result, at least in part, from deregulation of this receptor.
  • the HER-2 gene (c-erbB-2, neu) encodes a 185kDa transmembrane tyrosine kinase receptor that has partial homology with other members of the epidermal growth factor receptor family [Shih, C, Padhy, L. C, Murray, M., et al. Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts, Nature, 290, 261-264 (1981 )]. It is now known that normal human cells express a small constitutive amount of HER-2 protein on the plasma membrane.
  • HER-2 oncogene The activation of the HER-2 oncogene is believed to follow the binding of a yet unidentified growth factor ligand to the HER-2 receptor complex, which leads to heterodimerization, triggering a cascade of growth signals that culminates in gene activation. More specifically, the epidermal growth factor family can be subdivided into four groups based on their receptor-binding specificities (HER-1 , HER-2, HER-3, and HER-4). HER-2 is the preferred heterodimerization partner of all other HER receptors. Over expression of HER-2 has been demonstrated to lead to increased tumorigenicity, tumor invasiveness, increased metastatic potential, and altered sensitivity to hormonal and chemotherapeutic agents in transfection studies in cellular and animal models [Pegram, M.
  • HER-2 protein over expression has been reported to occur in approximately 30% of invasive human breast cancers, with HER-2 gene amplification detected in 95% or more of the specimens found to over express HER-2 protein, [Gebhardt, F., Zanker, K., Brandt, B. Differential expression of alternatively spliced c-erbB-2 mRNA in primary tumors, lymph node metastases, and bone marrow micro metastases from breast cancer patients Biochem. Biophys. Res. Commun., 247, 319-323 (1998)].
  • This invention provides a compound of formula 1 :
  • Ri is halogen
  • R 2 is a pyridinyl, optionally substituted pyrimidine, thiazole, or an optionally substituted phenyl ring wherein the phenyl or pyrimidine ring may be unsubstituted, mono-substituted, or di-substituted; and R 3 is -0- or-S-.
  • the compounds of this invention are certain substituted 3-cyano quinolines.
  • the quinoline ring system will be numbered as indicated in the formula below; the numbering for the quinazoline ring system is also shown :
  • the pharmaceutically acceptable salts of the compounds of this invention are those derived from such organic and inorganic acids as: acetic, lactic, citric, tartaric, succinic, maleic, malonic, gluconic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic, and similarly known acceptable acids.
  • halogen is F, Cl, Br, or I.
  • substituted includes attaching a methyl group to a ring carbon
  • the compounds of this invention may contain one or more asymmetric carbons atoms; in such cases, the compounds of this invention include the individual diasteromers, the racemates, and the individual R and S entantiomers thereof. Some of the compounds of this invention may contain one or more double bonds; in such cases, the compounds of this invention include each of the possible configurational isomers as well as mixtures of these isomers.
  • a "neoplasm" is defined as cells selected from the breast, kidney, bladder, mouth, larynx, esophagus, stomach, colon, ovary, pancreas, brain, prostrate and lung having a morphology not found in the majority of the cells of a mammal.
  • the present invention provides for a method of inhibiting the neoplasm.
  • the method comprises contacting a cell with an amount of a compound effective to decrease or prevent HER-2 function.
  • the cell may be a mammalian cell and more specifically a human cell.
  • the cell may also be a bacterial cell such as for example E coll.
  • the cell may include but is not limited to, a neuronal cell, an endothelial cell, a glial cell, a microglial cell, a smooth muscle cell, a somatic cell, a bone marrow cell, a liver cell, an intestinal cell, a germ cell, a myocyte, a mononuclear phagocyte, an endothelial cell, a tumor cell, a lymphocyte cell, a mesangial cell, a retinal epithelial cell, a retinal vascular cell, a ganglion cell or a stem cell.
  • the cell may be a normal cell, an activated cell, a neoplastic cell, a diseased cell, or an infected cell.
  • the present invention provides a method for the treatment or prevention of a neoplasm in a mammal.
  • the present invention accordingly provides to a mammal, a pharmaceutical composition that comprises a compound of this invention in combination or association with a pharmaceutically acceptable carrier.
  • the compound of this invention may be administered alone or in combination with other therapeutically effective compounds or therapies for the treatment or prevention of the neoplasm.
  • the compounds may be provided orally, by intralesional, intraperitoneal, intramuscular or intravenous injection; infusion; liposome-mediated delivery; topical, nasal, anal, vaginal, sublingual, uretheral, transdermal, intrathecal, ocular or otic delivery.
  • a compound of the invention is in the form of a unit dose. Suitable unit dose forms include tablets, capsules and powders in sachets or vials. Such unit O 2005/034955
  • dose forms may contain from 0.1 to 300 mg of a compound of the invention and preferably from 2 to 100 mg. Still further preferred unit dosage forms contain 5 to 50 mg of a compound of the present invention.
  • the compounds of the present invention can be administered orally at a dose range of about 0.01 to 100 mg/kg or preferably at a dose range of 0.1 to 10 mg/kg. Such compounds may be administered from 1 to 6 times a day, more usually from 1 to 4 times a day.
  • the effective amount will be known to one of skill in the art; it will also be dependent upon the form of the compound. One of skill in the art could routinely perform empirical activity tests to determine the bioactivity of the compound in bioassays and thus determine what dosage to administer.
  • the compounds of the invention may be formulated with conventional excipients, such as a filler, a disintegrating agent, a binder, a lubricant, a flavoring agent, a color additive, or a carrier.
  • the carrier may be for example a diluent, an aerosol, a topical carrier, an aqueous solution, a nonaqueous solution or a solid carrier.
  • the carrier may be a polymer or a toothpaste.
  • a carrier in this invention encompasses any of the standard pharmaceutically accepted carriers, such as phosphate buffered saline solution, acetate buffered saline solution, water, emulsions such as an oil/water emulsion or a triglyceride emulsion, various types of wetting agents, tablets, coated tablets and capsules. When provided orally or topically, such compounds would be provided to a subject by delivery in different carriers. Typically, such carriers contain excipients such as starch, milk, sugar, certain types of clay, gelatin, stearic acid, talc, vegetable fats or oils, gums, or glycols.
  • PBS phosphate buffered saline
  • vegetable fats, creams, salves, ointments or gels may be used for topical delivery.
  • compositions are liquids or lyophilized or otherwise dried formulations and include diluents of various buffer content (for example, Tris-HCI, acetate, phosphate), pH and ionic strength, additives such as albumins or gelatin to prevent absorption to surfaces, detergents (for example, TWEEN 20, TWEEN 80, PLURONIC F68, bile acid salts), solubilizing agents (for example, glycerol, polyethylene glycerol), anti-oxidants (for example ascorbic acid, sodium metabisulfate), preservatives (for example, thimerosal, benzyl alcohol, parabens), bulking substances or tonicity modifiers (for example, lactose, mannitol), covalent attachment of polymers such as Tris-HCI, acetate, phosphate), pH and ionic strength, additives such as albumins or gelatin to prevent absorption to surfaces, detergents (for example, TWEEN 20, TWEEN 80, PLURONIC
  • compositions will influence the physical state, solubility, stability, rate of in vivo release, and rate of in vivo clearance of the compound or composition.
  • the choice of compositions will depend on the physical and chemical properties of the compound capable of treating or preventing a neoplasm.
  • the compound of the present invention may be delivered locally via a capsule that allows a sustained release of the compound over a period of time.
  • Controlled or sustained release compositions include formulation in lipophilic depots (for example, fatty acids, waxes, oils).
  • the present invention further provides a compound of the invention for use as an active therapeutic substance for preventing neoplasm.
  • the present invention further provides a method of treating neoplasm in humans, which comprises administering to the infected individual an effective amount of a compound or a pharmaceutical composition of the invention.
  • the compounds of this invention can be prepared as outlined in Flowsheet 1 wherein R-i, R 2 , and R 3 are as described above.
  • the amino group of compound 1 can be protected as an amide group by acetylation using acetic anhydride in a solvent such as acetic acid.
  • the hydroxyl group of 2 can be alkylated with an alkyl bromide, iodide, tosylate, or mesyiate using potassium carbonate in a refluxing solvent such as acetone.
  • the nitro group of 3 can be reduced using catalytic hydrogenation to give the substituted aniline 4. Heating of 4 with reagent 5 with or without a solvent gives the intermediate 6.
  • Refluxing 6 in a high boiling solvent such as Dowtherm results in cyclization to the hydroxy quinoline 7.
  • This can be chlorinated by heating in phosphorous oxychloride to give the chloro derivative 8.
  • Condensation of 8 with an aniline of formula 9 in a refluxing solvent such as ethanol in the presence of a catalytic amount of acid yields the intermediate 10.
  • the acetate group of 10 can be removed by hydrolysis using acidic or basic conditions followed by neutraliztion to give 11.
  • the intermediate 11 can be acylated with an amino acid chloride 12 (as the hydrochloride salt) to give the compounds of this invention of formula 13.
  • Methods used to prepare the compounds in U.S. patent 6,288,082, WO- 9633978 and WO-9633980 can also be used to prepare the compounds of this invention and are hereby incorporated by reference.
  • This compound was prepared from 3-chloro-4-fluoronitrobenzene and 3-fluorobenzyl alcohol using the method described above in Example 13.
  • the above-identified compound was prepared from 3-chloro-4-(2- pyridylmethoxy)nitrobenzene and 4-chloro-3-cyano-7-ethoxy-6-N-acetylamino- quinoline using the method described above in Example 15.
  • the reaction produced a mixture of 4-bromo-(and chloro)-but-2-enoic acid ⁇ 4-[3-chloro-4- (thiazol-2-ylsulfanyl)-phenylamino]-3-cyano-7-methoxy-quinolin-6-yl ⁇ -amide.
  • a 300 mL portion of the solution was cooled to 0 e C and 2.38 g (26.7 mmol) (2- methoxyethyl)-methylamine in 11 mL THF was added dropwise. After the reaction had warmed to room temperature, 401 mg (0.5 eq) of sodium iodide was added and the solution was stirred overnight.
  • Representative compounds of this invention were evaluated in several standard pharmacological test procedures that showed that the compounds of this invention possess significant activity as inhibitors of HER-2 and are antiproliferative agents. Based on the activity shown in the standard pharmacological test procedures, the compounds of this invention are therefore useful as antineoplastic agents.
  • the test procedures used and results obtained are shown below.
  • example 1 , example 2 and example 3 are potent inhibitors of the HER-2 enzyme, example 20 is not.
  • Purified recombinant C-terminal fragment of each enzyme is incubated with ATP in the absence or presence of a range of compound concentrations.
  • Autophosphorylation of the receptors was evaluated with phosphotyrosine antibodies in an ELISA format.
  • IC 50 IC 50
  • Table 1 all three inhibitors reduced enzyme activity by 50% (IC 50 ) at concentrations between 33-65 nM
  • example 1 , example 2, and example 3 repressed the proliferation of a mouse fibroblast cell line transfected with the HER-2 oncogene (3T3/neu) by 50% (IC 50 ) at 3-5 nM (Table 2). This value was substantially lower than that obtained with the isogenic untransfected cells (3T3; IC 50 683-906 nM), indicating a high degree of selectivity for this oncogenic pathway. Cells were incubated with various concentrations of compound for 2 days (6 days for BT474 cells).
  • SRB protein binding dye assay
  • Receptor Phosphorylation Compounds that repressed the proliferation of a mouse fibroblast cell line transfected with the HER-2 oncogene (3T3/neu) by 50% (IC 50 ) ⁇ 0.05 vg/ml in Table 2 above were tested for in vitro phosphorylation.
  • a mouse fibroblast cell line transfected with the HER-2 oncogene (3T3/neu) by 50% (IC 50 ) ⁇ 0.05 vg/ml in Table 2 above were tested for in vitro phosphorylation.
  • cells BT474 and A431 , respectively
  • Protein extracts were analyzed by immunoblotting using phospho-tyrosine antibodies. Blots were quantified by densitometric scanning. Concentration of compound (nM) which inhibits phosphorylation by 50% was determined.
  • Example 1 decreased ligand-independent receptor phosphorylation by 50% (IC 50 ) at 5-23 nM in BT474 cells (Table 3). They also repressed EGF-dependent phosphorylation of EGFR in A431 cells at a comparable dose (IC 50 3-7 nM). Table 3
  • example 3 The in vivo antitumor activity of example 3 was evaluated in tumor xenograft models. Tumor cells (grown in tissue culture) or tumor fragments were implanted subcutaneously in female nude mice. Treatment was initiated after tumors had reached a size of 90-200 mg, following random assignment of the animals to different treatment groups (staging). Alternatively (3T3lneu), treatment was initiated the day after tumor implantation, due to the rapid outgrowth of these tumors. Compounds were formulated in 0.5% Methocel-0.4% polysorbate-80 (Tween-80) and administered daily, PO, by gavage. Tumor mass [(L X W 2 ) 12] was determined every 7 days. Statistical significance of compound effects was evaluated using Student's t-test.
  • example 3 inhibited tumor growth when administered to animals at 20 mg/kg/day (65% inhibition, day 21), 40 mg/kg/day (97% inhibition), and 80 mg/kg/day (99% inhibition). These results were almost identical to those obtained with example 2 treatment (53%, 95%, and 98% inhibition, respectively at 20, 40 and 80 mg/kg/day).
  • EXAMPLE 3 treatment produced a statistically- significant inhibition of tumor growth (21-33%) at a dose of 10 mg/kg/day.
  • the minimum efficacious dose was estimated to be 10 mg/kg/day. This is the smallest dose that produces a sustained, statistically- significant (p ⁇ 0.05) reduction of tumor growth.
  • example 3 was next studied in xenografts of HER-2-dependent human tumor cell lines.
  • example 3 treatment reduced tumor growth when dosed between 10 mg/kg/day and 40 mg/kg/day.
  • Maximum inhibition was observed on day 21 , and ranged from 59% (10/mg/kg/day) to 96% (40 mg/kg/day).
  • inhibition ranged from 76% (10 mg/kg/day) to 95% (40 mg/kg/day). Similar results were obtained in two other independent experiments.
  • example 3 In animals bearing xenografts of SUM-190 (a second HER-2-dependent breast cancer cell line), example 3 treatment resulted in substantial repression of tumor growth when dosed at 40 mg/kg/day (94% inhibition, day 28).
  • Example 3 was also effective against xenografts of SK-OV-3 (a HER-2-dependent human ovarian carcinoma cell line).
  • example 3 was active between 20 mg/kg/day (86% inhibition, day 35) and 60 mg/kg/day (91 % inhibition).
  • the MED in the HER-2 overexpressing human xenograft models was estimated at 10 mg/kg/day, similar to example 2. In these studies, there was no decrease in tumor size below the initial size at the start of dosing. Furthermore, tumors showed evidence of re-growth when treatment was completed, which is consistent with a non-cytotoxic mode of action for example 3.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

This invention provides compounds of formula (I), having the structure wherein R1, R2, R3 are described within the specification. The compounds act as anti-cancer agents by inhibition of HER-2 and EGFR.

Description

SUBSTITUTED QUINOLINES AS PROTEIN TYROSINE KINASE ENZYME INHIBITORS
BACKGROUND OF THE INVENTION
This invention relates to certain substituted 3-cyano quinoline compounds as well as the pharmaceutically acceptable salts thereof. The compounds of the present invention inhibit the HER-2 and epidermal growth factor receptor (EGFR) enzyme thereby inhibiting the abnormal growth of certain cell types. The compounds of this invention are anti-cancer agents and are useful for the treatment of cancer in mammals. This invention also relates to the use of 3-cyano quinolines in the treatment of cancer and the pharmaceutical preparations containing them. Protein tyrosine kinases are a class of enzymes that catalyze the transfer of a phosphate group from ATP to a tyrosine residue located on a protein substrate. Protein tyrosine kinases clearly play a role in normal cell growth. Many of the growth factor receptor proteins function as tyrosine kinases and it is by this process that they effect signaling. The interaction of growth factors with these receptors is a necessary event in normal regulation of cell growth. However, under certain conditions, as a result of either mutation or over expression, these receptors can become deregulated, the result of which is uncontrolled cell proliferation which can lead to tumor growth and ultimately to the disease known as cancer [Walks, A.F., Adv. Cancer Res., 60, 43 (1993) and Parsons, J.T.; Parsons, S.J., Important Advances in Oncology, DeVita, V.T. Ed., J.B. Lippincott Co., Phila., 3 (1993) ]. Among the growth factor receptor kinases and their proto-oncogenes that have been identified and which are targets of the compounds of this invention are the epidermal growth factor receptor kinase (EGF-R kinase, the protein product of the erbB oncogene), and the product produced by the erbB-2 (also referred to as the neu or5 HER-2) oncogene. Since the phosphorylation event is a necessary signal for cell division to occur and since over expressed or mutated kinases have been associated with cancer, an inhibitor of this event, a protein tyrosine kinase inhibitor, will have therapeutic value for the treatment of cancer and other diseases characterized by uncontrolled or abnormal cell growth. For example, over expression of the receptor0 kinase product of the erbB-2 oncogene has been associated with human breast and ovarian cancers [Slamon, D. J., et. al., Science, 244, 707 (1989) and Science, 235,
-l- 1146 (1987)]. Deregulation of EGF-R kinase has been associated with epidermoid tumors [Reiss, M., er a/., Cancer Res., 51, 6254 (1991)], breast tumors [Macias, A., et. al., Anticancer Res., 7, 459 (1987)], and tumors involving other major organs [Gullick, W. J., Brit. Med. Bui/., 47, 87 (1991)]. Because of the importance of the role played by deregulated receptor kinases in the pathogenesis of cancer, many recent studies have dealt with the development of specific PTK inhibitors as potential anti- cancer therapeutic agents [some recent reviews: Burke. T. R., Drugs Future, 17, 119 (1992) and Chang, C. J.; Geahlen, R. L, J. Nat. Prod., 55, 1529 (1992)]. The compounds of this invention inhibit the kinase activity of EGF-R and are therefore useful for treating certain disease states, such as cancer, that result, at least in part, from deregulation of this receptor.
The HER-2 gene (c-erbB-2, neu) encodes a 185kDa transmembrane tyrosine kinase receptor that has partial homology with other members of the epidermal growth factor receptor family [Shih, C, Padhy, L. C, Murray, M., et al. Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts, Nature, 290, 261-264 (1981 )]. It is now known that normal human cells express a small constitutive amount of HER-2 protein on the plasma membrane. The activation of the HER-2 oncogene is believed to follow the binding of a yet unidentified growth factor ligand to the HER-2 receptor complex, which leads to heterodimerization, triggering a cascade of growth signals that culminates in gene activation. More specifically, the epidermal growth factor family can be subdivided into four groups based on their receptor-binding specificities (HER-1 , HER-2, HER-3, and HER-4). HER-2 is the preferred heterodimerization partner of all other HER receptors. Over expression of HER-2 has been demonstrated to lead to increased tumorigenicity, tumor invasiveness, increased metastatic potential, and altered sensitivity to hormonal and chemotherapeutic agents in transfection studies in cellular and animal models [Pegram, M. D., Finn, R. S., Arzoo, K., et al. The effect of HER-2/neu over expression on chemotherapeutic drug sensitivity in human breast and ovarian cells Oncogene, 15, 537-547 (1997)]. HER-2 protein over expression has been reported to occur in approximately 30% of invasive human breast cancers, with HER-2 gene amplification detected in 95% or more of the specimens found to over express HER-2 protein, [Gebhardt, F., Zanker, K., Brandt, B. Differential expression of alternatively spliced c-erbB-2 mRNA in primary tumors, lymph node metastases, and bone marrow micro metastases from breast cancer patients Biochem. Biophys. Res. Commun., 247, 319-323 (1998)].
U.S. patent 6,288,082 issued September 11 , 2001 (the '082 patent) discloses substituted 3-cyano quinoline compounds that inhibit epidermal growth factor receptor (EGFR). The compounds of this application are distinguished from those of the '082 patent in their ability to act as potent HER-2 inhibitors.
BRIEF SUMMARY OF THE INVENTION
This invention provides a compound of formula 1 :
wherein:
Ri is halogen;
R2 is a pyridinyl, optionally substituted pyrimidine, thiazole, or an optionally substituted phenyl ring wherein the phenyl or pyrimidine ring may be unsubstituted, mono-substituted, or di-substituted; and R3 is -0- or-S-.
In one embodiment the compounds of this invention include:
(E)-N-{4-[4-(benzyloxy)-3-chloroanilino]-3-cyano-7-ethoxy-6-quinolinyl}-4- (dimethylamino)-2-buteπamide;
(E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4- (dimethylamino)-2-butenamide;
(E)-N-(4-{3-chloro-4-[(3-fluorobenzyl)oxy]anilino}-3-cyano-7-ethoxy-6-quinolinyl)-4- (dimethylamino)-2-butenamide;
(2E)-N-(4-{[3-chloro-4-(1 ,3-thiazol-2-ylsulfanyl)phenyl]amino}-3-cyano-7-methoxy-6- quinolinyl)-4-(dimethylamino)-2-butenamide;
(E)-N-(4-{3-chloro-4-[(4,6-di-methyl-2-pyrimidinyl)sulfanyl]anilino}-3-cyano-7-ethoxy- 6-quinolinyl)-4-(dimethylamino)-2-butenamide;
(E)-N-{4-[3-chloro-4-(1 ,3-thiazol-2-ylsulfanyl)anilino]-3-cyano-7-methoxy-6- quinolinyl}-4-[(2-methoxyethyl)(methyl)amino]-2-butenamide;
or a pharmaceutically acceptable salts thereof. The following experimental details are set forth to aid in an understanding of the invention, and are not intended, and should not be construed, to limit in any way the invention set forth in the claims that follow thereafter.
DETAILED DESCRIPTION OF THE INVENTION
The compounds of this invention are certain substituted 3-cyano quinolines. Throughout this patent application, the quinoline ring system will be numbered as indicated in the formula below; the numbering for the quinazoline ring system is also shown :
The pharmaceutically acceptable salts of the compounds of this invention are those derived from such organic and inorganic acids as: acetic, lactic, citric, tartaric, succinic, maleic, malonic, gluconic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic, and similarly known acceptable acids. For purposes of this invention "halogen" is F, Cl, Br, or I.
As used herein, the term "substituted" includes attaching a methyl group to a ring carbon
The compounds of this invention may contain one or more asymmetric carbons atoms; in such cases, the compounds of this invention include the individual diasteromers, the racemates, and the individual R and S entantiomers thereof. Some of the compounds of this invention may contain one or more double bonds; in such cases, the compounds of this invention include each of the possible configurational isomers as well as mixtures of these isomers. For purposes of this invention a "neoplasm" is defined as cells selected from the breast, kidney, bladder, mouth, larynx, esophagus, stomach, colon, ovary, pancreas, brain, prostrate and lung having a morphology not found in the majority of the cells of a mammal.
In one embodiment, the present invention provides for a method of inhibiting the neoplasm. The method comprises contacting a cell with an amount of a compound effective to decrease or prevent HER-2 function. The cell may be a mammalian cell and more specifically a human cell. The cell may also be a bacterial cell such as for example E coll. The cell may include but is not limited to, a neuronal cell, an endothelial cell, a glial cell, a microglial cell, a smooth muscle cell, a somatic cell, a bone marrow cell, a liver cell, an intestinal cell, a germ cell, a myocyte, a mononuclear phagocyte, an endothelial cell, a tumor cell, a lymphocyte cell, a mesangial cell, a retinal epithelial cell, a retinal vascular cell, a ganglion cell or a stem cell. The cell may be a normal cell, an activated cell, a neoplastic cell, a diseased cell, or an infected cell.
In another embodiment, the present invention provides a method for the treatment or prevention of a neoplasm in a mammal. The present invention accordingly provides to a mammal, a pharmaceutical composition that comprises a compound of this invention in combination or association with a pharmaceutically acceptable carrier. The compound of this invention may be administered alone or in combination with other therapeutically effective compounds or therapies for the treatment or prevention of the neoplasm.
The compounds may be provided orally, by intralesional, intraperitoneal, intramuscular or intravenous injection; infusion; liposome-mediated delivery; topical, nasal, anal, vaginal, sublingual, uretheral, transdermal, intrathecal, ocular or otic delivery. In order to obtain consistency in providing the compound of this invention it is preferred that a compound of the invention is in the form of a unit dose. Suitable unit dose forms include tablets, capsules and powders in sachets or vials. Such unit O 2005/034955
dose forms may contain from 0.1 to 300 mg of a compound of the invention and preferably from 2 to 100 mg. Still further preferred unit dosage forms contain 5 to 50 mg of a compound of the present invention. The compounds of the present invention can be administered orally at a dose range of about 0.01 to 100 mg/kg or preferably at a dose range of 0.1 to 10 mg/kg. Such compounds may be administered from 1 to 6 times a day, more usually from 1 to 4 times a day. The effective amount will be known to one of skill in the art; it will also be dependent upon the form of the compound. One of skill in the art could routinely perform empirical activity tests to determine the bioactivity of the compound in bioassays and thus determine what dosage to administer.
The compounds of the invention may be formulated with conventional excipients, such as a filler, a disintegrating agent, a binder, a lubricant, a flavoring agent, a color additive, or a carrier. The carrier may be for example a diluent, an aerosol, a topical carrier, an aqueous solution, a nonaqueous solution or a solid carrier. The carrier may be a polymer or a toothpaste. A carrier in this invention encompasses any of the standard pharmaceutically accepted carriers, such as phosphate buffered saline solution, acetate buffered saline solution, water, emulsions such as an oil/water emulsion or a triglyceride emulsion, various types of wetting agents, tablets, coated tablets and capsules. When provided orally or topically, such compounds would be provided to a subject by delivery in different carriers. Typically, such carriers contain excipients such as starch, milk, sugar, certain types of clay, gelatin, stearic acid, talc, vegetable fats or oils, gums, or glycols. The specific carrier would need to be selected based upon the desired method of delivery, for example, phosphate buffered saline (PBS) could be used for intravenous or systemic delivery and vegetable fats, creams, salves, ointments or gels may be used for topical delivery.
The compounds of the present invention may be delivered together with suitable diluents, preservatives, solubilizers, emulsifiers, adjuvants and/or carriers useful in treatment or prevention of neoplasm. Such compositions are liquids or lyophilized or otherwise dried formulations and include diluents of various buffer content (for example, Tris-HCI, acetate, phosphate), pH and ionic strength, additives such as albumins or gelatin to prevent absorption to surfaces, detergents (for example, TWEEN 20, TWEEN 80, PLURONIC F68, bile acid salts), solubilizing agents (for example, glycerol, polyethylene glycerol), anti-oxidants (for example ascorbic acid, sodium metabisulfate), preservatives (for example, thimerosal, benzyl alcohol, parabens), bulking substances or tonicity modifiers (for example, lactose, mannitol), covalent attachment of polymers such as polyethylene glycol, complexation with metal ions, or incorporation of the compound into or onto particulate preparations of hydrogels or liposomes, micro-emulsions, micelles, unilamellar or multilamellar vesicles, erythrocyte ghosts, or spheroblasts. Such compositions will influence the physical state, solubility, stability, rate of in vivo release, and rate of in vivo clearance of the compound or composition. The choice of compositions will depend on the physical and chemical properties of the compound capable of treating or preventing a neoplasm. The compound of the present invention may be delivered locally via a capsule that allows a sustained release of the compound over a period of time. Controlled or sustained release compositions include formulation in lipophilic depots (for example, fatty acids, waxes, oils).
The present invention further provides a compound of the invention for use as an active therapeutic substance for preventing neoplasm.
The present invention further provides a method of treating neoplasm in humans, which comprises administering to the infected individual an effective amount of a compound or a pharmaceutical composition of the invention.
The compounds of this invention can be prepared as outlined in Flowsheet 1 wherein R-i, R2, and R3 are as described above. The amino group of compound 1 can be protected as an amide group by acetylation using acetic anhydride in a solvent such as acetic acid. The hydroxyl group of 2 can be alkylated with an alkyl bromide, iodide, tosylate, or mesyiate using potassium carbonate in a refluxing solvent such as acetone. The nitro group of 3 can be reduced using catalytic hydrogenation to give the substituted aniline 4. Heating of 4 with reagent 5 with or without a solvent gives the intermediate 6. Refluxing 6 in a high boiling solvent such as Dowtherm results in cyclization to the hydroxy quinoline 7. This can be chlorinated by heating in phosphorous oxychloride to give the chloro derivative 8. Condensation of 8 with an aniline of formula 9 in a refluxing solvent such as ethanol in the presence of a catalytic amount of acid yields the intermediate 10. The acetate group of 10 can be removed by hydrolysis using acidic or basic conditions followed by neutraliztion to give 11. The intermediate 11 can be acylated with an amino acid chloride 12 (as the hydrochloride salt) to give the compounds of this invention of formula 13. Methods used to prepare the compounds in U.S. patent 6,288,082, WO- 9633978 and WO-9633980 can also be used to prepare the compounds of this invention and are hereby incorporated by reference.
Flowsheet 1
In addition to the method described herein above, there a number of patent applications that describe methods that are useful for the preparation of the compounds of this invention. Although these methods describe the preparation of certain quinazolines, they are also applicable to the preparation of correspondingly substituted 3-cyanoquinolines and are hereby incorporated by reference. The chemical procedures described in the application WO-9633980 can be used to prepare the 3-cyanoquinoiine intermediates used in this invention wherein the substitution at position 6 is an aminoalkylalkoxy group. The chemical procedures described in the application WO-9633978 can be used to prepare the 3- cyanoquinoline intermediates used in this invention wherein the substitution at position 6 is an aminoalkylamino group.
Example 1
(E)-N-{4-[4-(benzyloxy)-3-chloroanilino]-3-cyano-7-ethoxy-6-quinolinyl}-4- (dimethylamino)-2-butenamide
A 1.74 ml (2.54 g, 0.02 moles) portion of oxalyl chloride was added to 3.31 grams (0.02 moles) of (E)-4-(dimethylamino)-2-butenoic acid hydrochloride in 75 ml of acetonitrile. To this was added a small drop of dimethylformamide. The reaction was heated and stirred in an oil bath at 63° for 20 minutes, giving an orange solution. This solution as concentrated in vacuo without the application of heat to about half its original volume. This solution was cooled in an ice bath and a solution of 4.45 g (0.01 moles) of the 6-amino-4-[4-(benzyloxy)-3-chloroanilino]-7-ethoxy-3- quinolinecarbonitrile in 50 ml of N-methyl pyrrolidone was added in a stream. The reaction was cooled and stirred for 2 hours. The reaction was poured onto 100 ml of saturated aqueous sodium bicarbonate in ice. On standing the resulting gum solidified and the solid was filtered. This solid was chromatographed on silica gel. The column was washed with 3 liters of 1 :19 methanoi-ethyl acetate, then the product was eluted with 3 liters of 1 :5:94 triethylamine-methanol-ethyl acetate. Concentration of the eluate gave a solid, which was filtered to give 2.96 grams of the title compound. From the filtrate was obtained an additional 1.0 grams of product. Total: 3.96 g.
Example 2
(E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4- (dimethylamino)-2-butenamide
A solution of (E)-4-(dimethylamino)-2-butenoic acid hydrochloride in 1.2 L of tetrahydrofuran (THF) and a catalytic amount of dimethylformide (DMF) (1.2 ml) was cooled to 0-5 °C. Oxalyl chloride (0.95 eq) was added dropwise and the mixture was warmed to 25-30 °C and stirred for 2 hours. The orange suspension was checked for complete consumption of oxalyl chloride by HPLC then cooled to 0-5 °C. A solution of 111 g of 4-[4-(2-pyridylmethoxy)-3-chloro]amino-6-amino-3-cyano-7- ethoxyquinoline in 1.47 L of 1 -methyl-2-pyrrolidinone was added dropwise and the mixture was stirred until < 1.0% of the starting aniline remained (3-16 hours). The reaction was quenched with water and the mixture was warmed to 40 °C. Aqueous sodium hydroxide was added to bring the pH to 10-11. The resulting precipitates were filtered hot and washed with water. The wet solids were heated to reflux (70-75 °C) in acetonitrile:THF (1.5:1 ) and the solution cooled over 3 hours to room temperature. The product was filtered and washed with acetonitrile:THF. The product was dried (50 °C, 10 mm Hg, 24 hours) to give 80-85% yield. Melting point of maleate salt 178 - 183 °C.
Example 3
(E)-N-(4-{3-chloro-4-[(3-fluorobenzyl)oxy]anilino}-3-cyano-7-ethoxy-6-quinolinyl)-4- (dimethylamino)-2-butenamide A solution of 108 g (E)-4-(dimethylamino)-2-butenoic acid hydrochloride in 1.1 L of tetrahydrofuran (THF) and a catalytic amount of dimethylformide (DMF) (1.2 ml) was cooled to 0-5 °C. Oxalyl chloride (0.95 eq) was added dropwise and the mixture was warmed to 25-30 °C and stirred for 2 hours. The orange suspension was checked for complete consumption of oxalyl chloride by HPLC then cooled to 0-5 °C. A solution of 150 g of 6-amino-4-[3-chloro-4-(3-fluorobenzyloxy)]anilino-3-cyano-7- ethoxy quinoline in 1.5 L of 1-methyl-2-pyrrolidinone was added dropwise and the mixture was stirred until < 1.0% of the starting aniline remained (3-16 hours). The reaction was quenched with water and the mixture was warmed to 40 °C. Aqueous sodium hydroxide (101 g in 750 ml) was added to bring the pH to 10-11. The resulting precipitates were filtered hot and washed with water. The wet solids were heated to reflux (70-75 °C) in acetonitrile:THF (1.5:1) and the solution was cooled over 3 hours to room temperature. The product was filtered and washed with acetonitrile:THF. The product was dried (50 °C, 10 mm Hg, 24 h) and obtained in 80-85% yield. Melting Point 165 - 167 °C
Example 4
4-Benzyloxy-3-chloro-nitrobenzene
A 15.43 g (0.275 moles) portion of solid (pellets) potassium hydroxide was added to a solution of 43.89 g (0.25 moles) of 3-chloro-4-fluoro nitrobenzene and 32.34 ml (33.79 grams, 0.373 moles) of benzyl alcohol in 220 ml of acetonitrile. The reaction was vigorously stirred with a mechanical stirrer overnight. The resulting solid was filtered. Concentration of the filtrate gave a second crop, which was also filtered. On standing more solid came out of this filtrate. This mixture was treated with ether, and the solid filtered. All solids were washed thoroughly with water, and combined to give 49.71 g of the title compound.
Example 5
4-BenzyIoxy-3-chloro-phenylamine
A mixture of 6.59 g (0.025 moles) of the 4-benzyloxy-3-chloro nitrobenzene (example 4), 4.19 g (0.075 moles) of iron powder, and 12.04 g (0.225 moles) of ammonium chloride in 100 ml of ethanol and 25 ml of water was stirred mechanically and refluxed for half an hour. The reaction was allowed to cool and stir for 1 hour. The mixture was filtered and solids were washed with ethanol. The combined filtrates were taken to dryness in vacuo. This solid was dissolved in methylene chloride and passed through Magnesol. Removal of the solvent from the filtrate in vacuo gave 5.60 g of title compound.
Example 6
N-{4-[4-(Benzyloxy)-3-chloroanilino]-3-cyano-7-ethoxy-6-quinolinyl}acetamide
A mixture of 4.17 g (0.0149 moles) of the N-(4-chloro-3-cyano-7-ethoxy-6- quinolinyl)acetamide, 4.04 g (0.0173 moles) of 4-benzyloxy-3-chloro-phenylamine (example 5), and 2.0 g (0.017 moles) of pyridine hydrochloride in 85 ml of isopropanol was stirred and refluxed in an oil bath for 30 minutes. The reaction was cooled in an ice bath, and the solid was collected by filtration and washed with isopropanol, and then with ether yielding 7.26 g of crude product as the hydrochloride salt. This material was purified by chromatography of the free base on silica gel by elution with 1 :39 methanol-methylene chloride.
Example 7
6-Amino-4-[4-(benzyloxy)-3-chloroanilino]-7-ethoxy-3-quinolinecarbonitrile
A solution of 298 mg (0.612 mmoles) of the purified N-{4-[4-(benzyloxy)-3- chloroanilino]-3-cyano-7-ethoxy-6-quinolinyl}acetamide (example 6) and 97 mg (1.73 mmoles) of potassium hydroxide in 10 ml of methanol was stirred and refluxed for 60 hours. On cooling a solid formed. This mixture was poured onto ice, and the resulting solid was filtered and washed with water. On drying, 242 mg of the title compound was obtained.
Example 8
2-Acetamido-5-nitrophenol
To 40O g of 2-amino-5-nitrophenol in a 5-L multi-necked flask equipped with a mechanical stirrer, reflux condenser, nitrogen inlet, 500-mL addition funnel, heating mantle, and a thermocouple attached to a temperature controller was added 1.6 L of acetic acid. The mixture was stirred at 60 °C as 398 g of acetic anhydride was added over 1.5 hours. After 1 hour, another 37 g of acetic anhydride was added. After another 1 hour, the mixture was cooled and diluted with 2 L of water. Solid was collected by filtration and washed with water and heptane. The solid was dried in a vacuum oven to give 509 g of the title compound.
Example 9
4-Acetamido-3-ethoxynitrobenzene
To 400 g of 2-acetamido-5-nitrophenol in a 12-L, 4-necked flask equipped with a reflux condenser, nitrogen inlet, thermocouple, addition funnel, and mechanical stirrer was added 790 g of potassium carbonate and 2.0 L of dimethylformamide. The mixture was stirred at 60 eC as 294 g of ethyl bromide was added over 30 minutes. After 1 hour, an additional 27 g of ethyl bromide was added and the mixture was stirred at 60 eC for another hour. The mixture was cooled to room temperature and poured into 4 L of water. After 30 minutes, the product was collected by filtration and washed with water and heptane. The product was dried in a vacuum oven at 60 eC to give 457 g of the title compound.
Example 10
3-(4-Acetamido-3-ethoxyaniline)-2-cyanopropenoic acid ethyl ester
A suspension of 4-acetamido-3-ethoxynitrobenzene compound in tetrahydrofuran (10 parts) was reduced to the aniline derivative using 10% Pd/C wet at 50 psi hydrogen and 30 °C for 2 hours. The resulting solution was filtered and concentrated to 2 parts of tetrahydrofuran. The concentrate was diluted with toluene and allowed to react with commercially available ethyl (ethoxymethylene)cyanoacetate at reflux for 16 hours. After reaction completion, the mixture was cooled. The precipitated product was collected by filtration, washed and dried. The product was obtained in 90% yield. Example 11
3-Cyano-7-ethoxy-4-hyd roxy-6-N -acetylq u i no I i ne
A solution of 210 g of 3-(4-acetamido-3-ethoxyaniline)-2-cyanopropenoic acid ethyl ester in 1 2 L of Dowtherm was stirred under nitrogen at 250 gC for 15 to 20 hours. The mixture was cooled to room temperature and solid was collected by filtration. The solid was washed with toluene and mixed with 1.2 L of tetrahydrofuran. The mixture was refluxed for 30 minutes and then cooled to room temperature. The solid was collected and washed with tetrahydrofuran. After drying 179.4 g of the title compound was obtained.
Example 12
4-Chloro-3-cyano-7-ethoxy-6-nitro quinoline
A stirred mixture of 300 g 3-cyano-7-ethoxy-4-hydroxy-6-N-acetylquinoline in 2.53 L of 1 ,2-diethoxyethane was heated to 80-85 °C. To this was added 224 ml of phosphorus oxychloride over 30-40 minutes. The mixture was stirred at 80-85 °C for 2-4 hours. The mixture was cooled, filtered over a celite pad and washed with 1 ,2- diethoxyethane. The filtrates were added over 1.5 hours to a cooled (0-10 °C) potassium carbonate (537 g in 1.5 L water) solution. The resulting yellow mixture was stirred for a minimum of 12 hours. The mixture was filtered and washed with hot water. The solids were dried (50 °C, 10 mm Hg, 24 h) to give the title compound in 30-50% yield. The material was used directly in the next step.
Example 13
3-Chloro-4-(2-pyridylmethoxy)nitrobenzene
A mixture of 160 g of potassium hydroxide and 2-pyridylcarbinol in 8 L acetonitrile was stirred for 20-30 minutes. To this was added 400 g of 3-chloro-4- fluoronitrobenzene and the mixture was stirred at 40 °C for a minimum of 18 hours until the reaction was complete. Water was added and the precipitated yellow solids were filtered and washed with water. The product was dried (40-50 °C, 10 mm Hg, 24 h) to the product in 85-95% yield.
Example 14
3-Chloro-4-(3-fluorobenzyloxy)nitrobenzene
This compound was prepared from 3-chloro-4-fluoronitrobenzene and 3-fluorobenzyl alcohol using the method described above in Example 13.
Example 15
6-Amino-4-(3-chloro-4-(3-fluorobenzyloxy))anilino-3-cyano-7-ethoxy quinoline
To a mixture of 400 g of 3-chloro-4-(3-fluorobenzyloxy)nitrobenzene (example 14) and 464 g zinc dust in 4 L of ethanol at 40-50 °C was added aqueous ammonium chloride (152 g in 800 ml water). After stirring a minimum of 2 hours, the reaction mixture was filtered hot through a celite pad and washed with hot ethanol. The filtrate was evaporaed and 1.72 L of 2-methyl THF, water and brine were added. The organic layer was separated and washed with water. The organic layer was evaporated and replaced with 3.8 L of ethanol. 4-Chloro-3-cyano-7-ethoxy-6-N- acetylamino-quinoline was added with a catalytic amount of methane sulfonic acid and the mixture was heated at 70-75 °C for a minimum of 2 hours until reaction completion. Concentrated 1.69 L HCI was added at 70-75 °C and held for a minimum of 2 hours until complete hydrolysis. Water was added and the mixture was cooled to 40 °C, solid was collected and washed with water. The wet cake was slurried in 5.4 L of methanol, 10% aqueous potassium carbonate (315 g in 2.8 L water) was added and the mixture was stirred for 2.5 hours. The mixture was filtered and washed with 1 :1 methanol :water. The product was dried (50 °C, 10 mm Hg, 24 hours) to give the title compound in 80-90% yield. Example 16
6-Amino-4-(4-(2-pyridylmethoxy)-3-chloro)anilino-3-cyano-7-ethoxyquinoline
The above-identified compound was prepared from 3-chloro-4-(2- pyridylmethoxy)nitrobenzene and 4-chloro-3-cyano-7-ethoxy-6-N-acetylamino- quinoline using the method described above in Example 15.
Example 20
4-Dimethyl-but-2-enoic acid [4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7- ethoxy-quinolin-6-yl]-amide
Example 21
N-{4-[3-Chloro-4-(1-methyl-1 H-imidazol-2-ylsulfanyl)-phenylamino]-3-cyano- quinolin-6-yl}-acrylamide
Example 22
6,7-Diethoxy-4-(1 H-indoI-6-ylamino)-quinoline-3-carbonitriie
Example 23
4-(2,3-Dihydro-benzo[1 ,4]dioxin-6-ylamino)-6,7-diethoxy-quinoline-3- carbonitrile
Example 24
4-(1 H-lndazol-6-ylamino)-6,7-bis-(2-methoxy-ethoxy)-quinoline-3-carbonitrile
Example 25
4-(1 ,4-Dioxo-1 ,2,3,4-tetrahydro-phthalazin-6-ylamino)-6,7-diethoxy-quinoline- 3-carbonitrile
Example 26
6,7-Diethoxy-4-(indan-5-ylamino)-quinoline-3-carbonitrile
Example 27
4-(2,4-Dioxo-1 ,4-dihydro-2H-benzo[d][1 ,3]oxazin-6-ylamino)-6,7-diethoxy- quinoline-3-carbonitrile
Example 28
6,7-Diethoxy-4-(1 -oxo-indan-5-ylamino)-quinoline-3-carbonitrile
Example 29
6,7-Diethoxy-4-(3-oxo-1 ,3-dihydro-isobenzofuran-5-ylamino)-quinoline-3- carbonitrile
Example 30
4-(1 ,1 -Dioxo-1 H-1 -benzo[b]thiophen-6-ylamino)-6,7-diethoxy-quinoline-3- carbonitrile
Example 31
7-Ethoxy-4-(1 H-indazol-6-ylamino)-6-methoxy-quinoline-3-carbonitrile
Example 32
6-Ethoxy-4-(1 H-indazol-6-ylamino)-7-methoxy-quinoline-3-carbonitrile
Example 33
6,7-Diethoxy-4-(1 -methyl-2,5-dioxo-2,3,4,5-tetrahydro-1 H- benzo[e][1 ,4]diazepin-7-ylamino)-quinoline-3-carbonitrile
Example 34
4-(1 H-lndazol-6-ylamino)-6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinoline- 3-carbonitrile
Example 35
4-({3-chloro-4-[(1 -methyl-1 H-imidazol-2-yl)sulfanyl]phenyl}amino)-7-methoxy- 6-nitro-3-quinolinecarbonitrile
Example 36
6-amino-4-({3-chloro-4-[(1 -methyl-1 H-imidazol-2-yl)sulfanyl]phenyl}amino)-7- methoxy-3-quinolinecarbonitrile
Example 37
(2E)-N-[4-({3-chloro-4-[(1-methyl-1 H-imidazol-2-yl)sulfanyl]phenyl}amino)-3- cyano-7-methoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide
Example 38
4-{[3-chloro-4-(1 ,3-thiazol-2-ylsulfanyl)phenyl]amino}-7-methoxy-6-nitro-3- quinolinecarbonitrile
Example 39
6-amino-4-{[3-chloro-4-(1 ,3-thiazol-2-ylsulfanyl)phenyl]amino}-7-methoxy-3- quinolinecarbonitrile
Example 40
(2E)-N-(4-{[3-chloro-4-(1 ,3-thiazol-2-ylsulfanyl)phenyl]amino}-3-cyano-7- methoxy-6-quinolinyl)-4-(dimethylamino)-2-butenamide
Example 41
4-[3-chloro-4-(1 H-imidazol-1 -yl)anilino]-7-methoxy-6-nitro-3-idazol-1 ■ yl)anilino]-7-methoxy-6-nitro-3-quinolinecarbonitrile
Example 42
6-amino-4-[3-chloro-4-(1 H-imidazol-1 -yl)anilino]-7-methoxy-3-4-(1 H-imidazol- 1-yl)anilino]-7-methoxy-3-quinolinecarbonitrile
Example 43
(E)-N-{4-[3-chloro-4-(1 H-imidazol-1 -yl)anilino]-3-cyano-7-methoxy-6- quinolinyl}-azol-1-yl)anilino]-4-(dimethylamino)-2-)anilino-2-butenamide
Example 44
4-{3-chloro-4-[(4-oxo-3,4-dihydro-2-quinazolinyl)sulfanyl]anilino}-7-methoxy- 6-hydro-2-quinazolinyl)sulfanyl]anilino}-7-methoxy-6-nitro-3- quinolinecarbonitrile
Example 45
6-amino-4-{3-chloro-4-[(4-oxo-3,4-dihydro-2-quinazolinyl)sulfanyl]anilino}-7- 3,4-dihydro-2-quinazolinyl)sulfanyl]anilino}-7-methoxy-3-quinolinecarbonitrile
Example 46
(E)-N-(4-{3-chloro-4-[(4-oxo-3,4-dihydro-2-quinazolinyl)sulfanyl]anilino}-3- fanyl]anilino}-3-cyano-7-methoxy-6-quinolinyl)-4-(dimethylamino)-2- butenamide
Example 47
(E)-N-(4-{4-[acetyl(3-pyridinylmethyl)amino]-3-chloroanilino}-3-cyano-7- methoxy-]-3-chloroanilino}-3-cyano-7-methoxy-6-quinolinyl)-4- (dimethylamino)-2-oanilino}-3-cyano-7-methoxy-6-quinolinyl)-4- (dimethylamino)-2-butenamide
Example 48
N-{2-chloro-4-[(3-cyano-7-methoxy-6-nitro-4-quinolinyl)amino]phenyl}-N-(3-7- methoxy-6-nitro-4-quinolinyl)amino]phenyl}-N-(3-pyridinylmethyl)acetamide
Example 49
N-{4-[(6-amino-3-cyano-7-methoxy-4-quinolinyl)amino]-2-chlorophenyl}-N-(3- methoxy-4-quinolinyl)amino]-2-chlorophenyl}-N-(3-pyridinylmethyl)acetamide
Example 50
N-(4-{[6-(acetylamino)-3-cyano-7-methoxy-4-quinolinyl]amino}-2- chlorophenyl)-N-ano-7-methoxy-4-quinolinyl]amino}-2-chlorophenyl)-N-(3- pyridinylmethyl)acetamide
Example 51
4-{3-chloro-4-[(1-methyl-1 H-imidazol-2-yl)sulfanyl]aniiino}-6-methoxy-7-[3-(4- morpholinyl)propoxy]-3-quinolinecarbonitrile
Example 52
4-(3-chloro-4-{[5-(trifluoromethyl)-1 ,3,4-thiadiazol-2-yl]amino}anilino)-7- ethoxy-6-nitro-3-quinolinecarbonitrile
Example 53
(E)-N-[4-(3-chloro-4-{[5-(trifluoromethyl)-1 ,3,4-thiadiazol-2-yl]amino}anilino)- 3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide
Example 54
4-[3-chloro-4-(4-pyridinyloxy)anilino]-7-ethoxy-6-nitro-3-quinolinecarbonitrile
Example 55
6-amino-4-[3-chloro-4-(4-pyridinyloxy)anilino]-7-ethoxy-3-quinolinecarbonitrile
Example 56
(E)-N-{4-[3-chloro-4-(4-pyridinyloxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4- (dimethyiamino)-2-butenamide
Example 57
4-{3-chloro-4-[(3-pyridinylmethyl)amino]anilino}-7-methoxy-6-nitro-3- quinolinecarbonitrile
Example 58
(E)-N-(4-{3-chloro-4-[(4-phenyl-1 ,3-thiazol-2-yl)sulfanyl]anilino}-3-cyano-7- methoxy-6-quinolinyl)-4-(dimethylamino)-2-butenamide
Example 59
6-amino-4-(3-chloro-4-{[5-(trifluoromethyl)-1 ,3,4-thiadiazol-2- yl]amino}anilino)-7-ethoxy-3-quinolinecarbonitrile
Example 60
4-[3-chloro-4-(1 H-imidazol-1 -ylmethyl)anilino]-7-ethoxy-6-nitro-3-
Example 61
6-amino-4-[3-chloro-4-(1 H-imidazol-1 -ylmethyl)anilino]-7-ethoxy-3-
Example 62
(E)-N-{4-[3-chloro-4-(1 H-imidazol-1 -ylmethyl)anilino]-3-cyano-7-ethoxy-6- quinolinyl}-4-(dimethylamino)-2-butenamide
Example 63
4-{3-chioro-4-[(4-methyl-2-pyrimidinyl)sulfanyl]anilino}-7-ethoxy-6-nitro-3- quinolinecarbonitrile
Example 64
6-amino-4-{3-chloro-4-[(4-methyl-2-pyrimidinyl)sulfanyl]anilino}-7-ethoxy-3- quinolinecarbonitrile
Example 65
(E)-N-(4-{3-chloro-4-[(4-methyl-2-pyrimidinyl)sulfanyl]anilino}-3-cyano-7- ethoxy-6-quinolinyl)-4-(dimethylamino)-2-butenamide
Example 66
(E)-N-(4-{3-chloro-4-[(4,6-dimethyl-2-pyrimidinyl)sulfanyl]anilino}-3-cyano-7- ethoxy-6-quinolinyl)-4-(dimethylamino)-2-butenamide
Example 67
7-ethoxy-6-nitro-4-[4-[(4-phenyl-1 ,3-thiazol-2-yl)sulfanyl]-3- (trifluoromethyI)anilino]-3-quinolinecarbonitrile
Example 68
6-Amino-7-ethoxy-4-[4-(4-phenyl-thiazol-2-ylsulfanyl)-3- trifluoromethyl-phenylamino]-quinoline-3-carbonitrile
Example 69
(E)-N-{3-cyano-7-ethoxy-4-[4-[(4-phenyl-1 ,3-thiazol-2-yl)sulfanyl]-3- (trifluoromethyl)anilino]-6-quinolinyl}-4-(dimethylamino)-2-butenamide
Example 70
(E)-N-(4-{3-chloro-4-[(5-phenyl-1 ,3-thiazol-2-yl)sulfanyl]anilino}-3-cyano-7- methoxy-6-quinolinyl)-4-(dimethylamino)-2-butenamide
Example 71
(E)-N-{4-[3-chioro-4-(1 ,3-thiazol-2-ylsulfanyl)anilino]-3-cyano-7-methoxy-6- quinolinyl}-4-[(2-methoxyethyl)(methyl)amino]-2-butenamide
(E)-N-{4-[3-chloro-4-(1 ,3-thiazol-2-ylsulfanyl)anilino]-3-cyano-7-methoxy-6- quinolinyl}-4-[(2-methoxyethyl)(methyl)amino]-2-butenamide was prepared by adding dropwise, 3.43 g (18.71 mmol, 1.95 mL) 4-bromocrotonyl chloride in 12 mL THF over 45 minutes to a stirred solution of 4.7 g (10.69 mmol) 6-amino-4-[3-chloro-4-(thiazol- 2-ylsulfanyl)-phenylamino]-7-methoxy-quinolin-3-carbonitrile in 588 mL THF containing 3.73 mL (21.36 mmol) diisopropylethylamine, at 0 °C under nitrogen. The reaction produced a mixture of 4-bromo-(and chloro)-but-2-enoic acid {4-[3-chloro-4- (thiazol-2-ylsulfanyl)-phenylamino]-3-cyano-7-methoxy-quinolin-6-yl}-amide. A 300 mL portion of the solution was cooled to 0 eC and 2.38 g (26.7 mmol) (2- methoxyethyl)-methylamine in 11 mL THF was added dropwise. After the reaction had warmed to room temperature, 401 mg (0.5 eq) of sodium iodide was added and the solution was stirred overnight. The solvents were evaporated to leave a red gum, which was partitioned between EtOAc and saturated NaHC03. After standing overnight, the layers were separated and the organic layer was dried and evaporated. Chromatography of the residue on a short column of Kieselgel 60, eluting with EtOAc, then EtOAc/15% MeOH, and finally EtOAc/15% MeOH/1% Et3N yielded 1.3 g (41%) of the product as a yellow glass; HRMS (ESI) m/z 595.13338 (M)+ , Δ = -2.28 mmu.
Example 72
(E)-N-(4-{3-chloro-4-[(4-phenyl-1 ,3-thiazol-2-yl)sulfanyl]anilino}-3-cyano-7- ethoxy-6-quinolinyl)-4-(dimethylamino)-2-butenamide
Example 73
4-{3-chloro-4-[(1-methyl-1 H-imidazol-2-yl)sulfanyl]anilino}-6-methoxy-7-[3- (1 H-1 ,2,3-triazol-1 -yl)propoxy]-3-quinolinecarbonitrile
Example 74
4-{3-chloro-4-[(4,6-dimethyl-2-pyrimidinyl)sulfanyl]anilino}-7-ethoxy-6-nitro- 3-quinolinecarbonitrile
Example 75
6-amino-4-{3-chloro-4-[(4,6-dimethyi-2-pyrimidinyl)sulfanyl]anilino}-7-ethoxy-3- quinolinecarbonitrile
Example 76
(2E)-N-{4-[3-chloro-4-(2-thienylmethoxy)anilino]-3-cyano-7-ethoxy-6- quinolinyl}-4-(dimethylamino)-2-butenamide
Representative compounds of this invention were evaluated in several standard pharmacological test procedures that showed that the compounds of this invention possess significant activity as inhibitors of HER-2 and are antiproliferative agents. Based on the activity shown in the standard pharmacological test procedures, the compounds of this invention are therefore useful as antineoplastic agents. The test procedures used and results obtained are shown below.
Kinase Assays: example 1 , example 2 and example 3 are potent inhibitors of the HER-2 enzyme, example 20 is not. Purified recombinant C-terminal fragment of each enzyme is incubated with ATP in the absence or presence of a range of compound concentrations. Autophosphorylation of the receptors was evaluated with phosphotyrosine antibodies in an ELISA format. In a cell-free autophosphorylation assay using the recombinant cytoplasmic domain of HER-2, all three inhibitors reduced enzyme activity by 50% (IC50) at concentrations between 33-65 nM (Table 1 ).
Table 1
They also inhibited EGFR under similar assay conditions at 33-92 nM.
Cell Proliferation Assays: example 1 , example 2, and example 3 repressed the proliferation of a mouse fibroblast cell line transfected with the HER-2 oncogene (3T3/neu) by 50% (IC50) at 3-5 nM (Table 2). This value was substantially lower than that obtained with the isogenic untransfected cells (3T3; IC50 683-906 nM), indicating a high degree of selectivity for this oncogenic pathway. Cells were incubated with various concentrations of compound for 2 days (6 days for BT474 cells). Cell survival was determined using a protein binding dye assay (SRB), (Rubinstein LV, Shoemaker RH, Paull KD, Simon RM, Tosini S, Skehan P, Scudiero DA, Monks A, Boyd MR. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J. Natl. Cancer Inst. 82(13):1113-8, 1990, Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82(13):1107-12, 1990). The concentration of drug (nM) which inhibits enzyme activity or cell proliferation by 50% is shown. The three inhibitors also inhibited two other HER-2 overexpressing breast cancer cell lines, SK-Br-3 and BT474 (IC50 2-4 nM), but were much less active on MDA-MB-435 and SW620 cells (a breast cancer and a colon cancer cell line, respectively), that are EGFR- and HER-2-negative. The compounds repressed the epidermal carcinoma cell line, A431 , that overexpresses EGFR (ICso 81-120 nM) (Table 2).
Table 2
Table 2
Table 2
Receptor Phosphorylation: Compounds that repressed the proliferation of a mouse fibroblast cell line transfected with the HER-2 oncogene (3T3/neu) by 50% (IC50) <0.05 vg/ml in Table 2 above were tested for in vitro phosphorylation. For Her-2 and EGFR phosphorylation assays, cells (BT474 and A431 , respectively) were incubated with various concentrations of compound for 3 hours at 37 °C. Protein extracts were analyzed by immunoblotting using phospho-tyrosine antibodies. Blots were quantified by densitometric scanning. Concentration of compound (nM) which inhibits phosphorylation by 50% was determined. Example 1 , Example 3 and HKI- 272 decreased ligand-independent receptor phosphorylation by 50% (IC50) at 5-23 nM in BT474 cells (Table 3). They also repressed EGF-dependent phosphorylation of EGFR in A431 cells at a comparable dose (IC50 3-7 nM). Table 3
IN VIVO: The in vivo antitumor activity of example 3 was evaluated in tumor xenograft models. Tumor cells (grown in tissue culture) or tumor fragments were implanted subcutaneously in female nude mice. Treatment was initiated after tumors had reached a size of 90-200 mg, following random assignment of the animals to different treatment groups (staging). Alternatively (3T3lneu), treatment was initiated the day after tumor implantation, due to the rapid outgrowth of these tumors. Compounds were formulated in 0.5% Methocel-0.4% polysorbate-80 (Tween-80) and administered daily, PO, by gavage. Tumor mass [(L X W2) 12] was determined every 7 days. Statistical significance of compound effects was evaluated using Student's t-test.
The activity of example 3 was first evaluated in xenografts of 313/neu cells example 3 inhibited tumor growth when administered to animals at 20 mg/kg/day (65% inhibition, day 21), 40 mg/kg/day (97% inhibition), and 80 mg/kg/day (99% inhibition). These results were almost identical to those obtained with example 2 treatment (53%, 95%, and 98% inhibition, respectively at 20, 40 and 80 mg/kg/day). In two other independent tests, EXAMPLE 3 treatment produced a statistically- significant inhibition of tumor growth (21-33%) at a dose of 10 mg/kg/day. Based on these studies, the minimum efficacious dose (MED) was estimated to be 10 mg/kg/day. This is the smallest dose that produces a sustained, statistically- significant (p<0.05) reduction of tumor growth.
The effect of example 3 was next studied in xenografts of HER-2-dependent human tumor cell lines. In animals bearing BT474 xenografts, example 3 treatment reduced tumor growth when dosed between 10 mg/kg/day and 40 mg/kg/day. Maximum inhibition was observed on day 21 , and ranged from 59% (10/mg/kg/day) to 96% (40 mg/kg/day). For example 2, inhibition ranged from 76% (10 mg/kg/day) to 95% (40 mg/kg/day). Similar results were obtained in two other independent experiments. In animals bearing xenografts of SUM-190 (a second HER-2- dependent breast cancer cell line), example 3 treatment resulted in substantial repression of tumor growth when dosed at 40 mg/kg/day (94% inhibition, day 28). Example 3 was also effective against xenografts of SK-OV-3 (a HER-2-dependent human ovarian carcinoma cell line). Here, example 3 was active between 20 mg/kg/day (86% inhibition, day 35) and 60 mg/kg/day (91 % inhibition). The MED in the HER-2 overexpressing human xenograft models was estimated at 10 mg/kg/day, similar to example 2. In these studies, there was no decrease in tumor size below the initial size at the start of dosing. Furthermore, tumors showed evidence of re-growth when treatment was completed, which is consistent with a non-cytotoxic mode of action for example 3.

Claims

WHAT IS CLAIMED IS:
A compound of formula 1 having the structure:
wherein:
R-i is halogen;
R2 is a pyridinyl, thiophene, optionally substituted pyrimidine, or an optionally substituted phenyl ring wherein the phenyl or pyrimidine ring may be unsubstituted, mono-substituted, or di-substituted; and
R3 is -O- or -S-
The compound according to claim 1 , which is:
(E)-N-{4-[4-(benzyloxy)-3-chloroanilino]-3-cyano-7-ethoxy-6-quinolinyl}-4- (dimethylamino)-2-butenamide or a pharmaceutically acceptable salt thereof.
The compound according to claim 1 , which is:
(E)-N-{4-[3-chloro-4-(2-pyridinyimethoxy)anilino]-3-cyano-7-ethoxy-6- quinolinyl}-4-(dimethylamino)-2-butenamide or a pharmaceutically acceptable salt thereof. The compound according to claim 1 , which is:
(E)-N-(4-{3-chloro-4-[(3-fluorobenzyl)oxy]anilino}-3-cyano-7-ethoxy-6- quinolinyl)-4-(dimethylamino)-2-butenamide or a pharmaceutically acceptable salt thereof.
The compound according to claim 1 , which is:
(2E)-N-(4-{[3-chloro-4-(1 ,3-thiazol-2-ylsulfanyl)phenyl]amino}-3-cyano-7- methoxy-6-quinolinyl)-4-(dimethylamino)-2-butenamide or a pharmaceutically acceptable salt thereof.
The compound according to claim 1 , which is:
(E)-N-(4-{3-chloro-4-[(4,6-di-methyl-2-pyrimidinyl)sulfanyl]anilino}-3-cyano-7- ethoxy-6-quinolinyl)-4-(dimethylamino)-2-butenamide or a pharmaceutically acceptable salt thereof.
A compound comprising (E)-N-{4-[3-chloro-4-(1 ,3-thiazol-2-ylsulfanyl)anilino]- 3-cyano-7-methoxy-6-quinolinyl}-4-[(2-methoxyethyl)(methyI)amino]-2- butenamide or a pharmaceutically acceptable salt thereof.
A method of treating, inhibiting the growth of, or eradicating neoplasms in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of formula 1 having the structure:
wherein:
RT is halogen; R2 is a pyridinyl, thiophene, optionally substituted pyrimidine, or an optionally substituted phenyl ring wherein the phenyl or pyrimidine ring may be unsubstituted, mono-substituted, or di-substituted; and R is -O- or -S-.
9. The method according to claim 8, wherein the compound is:
(E)-N-(4-[4-(benzyloxy)-3-chloroanilino]-3-cyano-7-ethoxy-6-quinolinyl}-4- (dimethylamino)-2-butenamide or a pharmaceutically acceptable salt thereof.
10. The method according to claim 8, wherein the compound is: (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6- quinolinyl}-4-(dimethylamino)-2-butenamide or a pharmaceutically acceptable salt thereof.
11. The method according to claim 8, wherein the compound is:
(E)-N-(4-{3-chloro-4-[(3-fluorobenzyl)oxy]anilino}-3-cyano-7-ethoxy-6- quinolinyl)-4-(dimethylamino)-2-butenamide or a pharmaceutically acceptable salt thereof.
12. The method according to claim 8, wherein the compound is:
(2E)-N-(4-{[3-chloro-4-(1 ,3-thiazol-2-ylsulfanyl)phenyl]amino}-3-cyano-7- methoxy-6-quinolinyl)-4-(dimethylamino)-2-butenamide or a pharmaceutically acceptable salt thereof.
13. The method according to claim 8, wherein the compound is:
(E)-N-(4-{3-chloro-4-[(4-methyl-2-pyrimidinyl)sulfanyl]anilino}-3-cyano-7- ethoxy-6-quinolinyl)-4-(dimethylamino)-2-butenamide or a pharmaceutically acceptable salt thereof.
4. A method of treating, inhibiting the growth of, or eradicating neoplasms in a mammal in need thereof which comprises administering to said mammal an effective amount of (E)-N-{4-[3-chloro-4-(1 ,3-thiazol-2-ylsulfanyl)anilino]-3- cyano-7-methoxy-6-quinolinyl}-4-[(2-methoxyethyl)(methyl)amino]-2- butenamide or a pharmaceutically acceptable salt thereof.
15. The method according to claim 14 wherein the neoplasm is selected from the group consisting of breast, kidney, bladder, mouth, larynx, esophagus, stomach, colon, ovary, pancreatic, brain, prostrate, and lung. 16. A pharmaceutical composition which comprises a compound of formula 1 having the structure
rmula 1 wherein:
RT is halogen;
R2 is a pyridinyl, thiophene, optionally substituted pyrimidine, or an optionally substituted phenyl ring wherein the phenyl or pyrimidine ring may be unsubstituted, mono-substituted, or di-substituted; and
R3 is -O- or -S-.
17. The pharmaceutical composition according to claim 16, which is: (E)-N-{4-[4-(benzyloxy)-3-chloroanilino]-3-cyano-7-ethoxy-6-quinolinyl}-4- (dimethylamino)-2-butenamide or a pharmaceutically acceptable salt thereof.
18. The pharmaceutical composition according to claim 16, which is:
(E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6- quinolinyl}-4-(dimethylamino)-2-butenamide or a pharmaceutically acceptable salt thereof.
19. The pharmaceutical composition according to claim 16, which is:
(E)-N-(4-{3-chloro-4-[(3-fluorobenzyl)oxy]anilino}-3-cyano-7-ethoxy-6- quinolinyI)-4-(dimethylamino)-2-butenamide or a pharmaceutically acceptable salt thereof.
20. The pharmaceutical composition according to claim 16, which is:
(E)-N-(4-{3-chloro-4-[(4-methyl-2-pyrimidinyl)sulfanyl]anilino}-3-cyano-7- ethoxy-6-quinoIinyl)-4-(dimethylamino)-2-butenamide or a pharmaceutically acceptable salt thereof. 21. A pharmaceutical composition comprising (E)-N-{4-[3-chloro-4-(1 ,3-thiazol-2- ylsulfanyl)anilino]-3-cyano-7-methoxy-6-quinolinyl}-4-[(2- methoxyethyl)(methyl)amino]-2-butenamide or a pharmaceutically acceptable salt thereof.
22. A method of inhibiting EGFR in a mammal which comprises administering to said mammal an effective amount of a compound of formula 1 having the structure:
wherein:
R1 is halogen;
R2 is a pyridinyl, thiophene, optionally substituted pyrimidine, or an optionally substituted phenyl ring wherein the phenyl or pyrimidine ring may be unsubstituted, mono-substituted, or di-substituted; and
R3 is -O- or -S-.
23. The method according to claim 22, wherein the compound is:
(E)-N-{4-[4-(benzyloxy)-3-chloroanilino]-3-cyano-7-ethoxy-6-quinolinyl}-4- (dimethylamino)-2-butenamide or a pharmaceutically acceptable salt thereof.
24. The method according to claim 22, wherein the compound is:
(E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6- quinolinyl}-4-(dimethyiamino)-2-butenamide or a pharmaceutically acceptable salt thereof.
25. The method according to claim 22, wherein the compound is:
(E)-N-(4-{3-chloro-4-[(3-fluorobenzyl)oxy]anilino}-3-cyano-7-ethoxy-6- quinolinyl)-4-(dimethylamino)-2-butenamide or a pharmaceutically acceptable salt thereof.
26. The method according to claim 22, wherein the compound is: (2E)-N-(4-{[3-chloro-4-(1 ,3-thiazol-2-ylsulfanyl)phenyl]amino}-3-cyano-7- methoxy-6-quinolinyl)-4-(dimethylamino)-2-butenamide or a pharmaceutically acceptable salt thereof.
27. The method according to claim 22, wherein the compound is:
(E)-N-(4-{3-chloro-4-[(4-methyl-2-pyrimidinyl)sulfanyl]anilino}-3-cyano-7- ethoxy-6-quinolinyl)-4-(dimethylamino)-2-butenamide or a pharmaceutically acceptable salt thereof.
28. A method of inhibiting Her-2 in a mammal which comprises administering to said mammal an effective amount of a compound of formula 1 having the structure:
wherein:
Ri is halogen;
R2 is a pyridinyl, thiophene, optionally substituted pyrimidine, or an optionally substituted phenyl ring wherein the phenyl or pyrimidine ring may be unsubstituted, mono-substituted, or di-substituted; and
R3 is -O- or -S-.
29. The method according to claim 28, wherein the compound is:
(E)-N-{4-[4-(benzyloxy)-3-chloroanilino]-3-cyano-7-ethoxy-6-quinolinyl}-4- (dimethylamino)-2-butenamide or a pharmaceutically acceptable salt thereof.
30. The method according to claim 28, wherein the compound is:
(E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6- quinoiinyl}-4-(dimethylamino)-2-butenamide or a pharmaceutically acceptable salt thereof.
31. The method according to claim 28, wherein the compound is:
(E)-N-(4-{3-chloro-4-[(3-fIuorobenzyl)oxy]aniIino}-3-cyano-7-ethoxy-6- quinolinyl)-4-(dimethylamino)-2-butenamide or a pharmaceutically acceptable salt thereof.
32. The method according to claim 28, wherein the compound is: (2E)-N-(4-{[3-chloro-4-(1 ,3-thiazol-2-ylsulfanyl)phenyl]amino}-3-cyano-7- methoxy-6-quinolinyl)-4-(dimethylamino)-2-butenamide or a pharmaceutically acceptable salt thereof.
33. The method according to claim 28, wherein the compound is:
(E)-N-(4-{3-chloro-4-[(4-methyl-2-pyrimidinyl)sulfanyl]anilino}-3-cyano-7- ethoxy-6-quinolinyl)-4-(dimethylamino)-2-butenamide or a pharmaceutically acceptable salt thereof.
EP03818857A 2003-09-15 2003-10-15 Substituted quinolines as protein tyrosine kinase enzyme inhibitors Withdrawn EP1670473A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66227303A 2003-09-15 2003-09-15
PCT/US2003/032612 WO2005034955A1 (en) 2003-09-15 2003-10-15 Substituted quinolines as protein tyrosine kinase enzyme inhibitors

Publications (1)

Publication Number Publication Date
EP1670473A1 true EP1670473A1 (en) 2006-06-21

Family

ID=34435322

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03818857A Withdrawn EP1670473A1 (en) 2003-09-15 2003-10-15 Substituted quinolines as protein tyrosine kinase enzyme inhibitors

Country Status (7)

Country Link
EP (1) EP1670473A1 (en)
AU (1) AU2003304497B2 (en)
BR (1) BR0318503A (en)
CA (1) CA2537978C (en)
MX (1) MXPA06002846A (en)
UA (1) UA85394C2 (en)
WO (1) WO2005034955A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104926669A (en) * 2014-03-18 2015-09-23 江苏豪森医药集团连云港宏创医药有限公司 Preparation method of trans-4-dimethylaminocrotonic acid hydrochloride

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101313702B1 (en) 2005-02-03 2013-10-04 와이어쓰 Pharmaceutical composition for treating gefitinib and／or erlotinib resistant cancer
CN101203494A (en) * 2005-05-25 2008-06-18 惠氏公司 Process for the synthesis of substituted 3-cyanoquinolines and intermediates thereof
EP1942937A1 (en) 2005-11-04 2008-07-16 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
KR20080112380A (en) * 2006-04-14 2008-12-24 아스트라제네카 아베 4-anilinoquinoline-3-carboxamide as a CSF-1R kinase inhibitor
US8022216B2 (en) * 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
BRPI0914790A2 (en) 2008-06-17 2015-10-20 Wyeth Llc use of a vinorelbine compound and a hki-272 compound, pharmaceutical composition and neoplasm treatment product and kit
US8669273B2 (en) 2008-08-04 2014-03-11 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
CN101723854A (en) 2008-10-24 2010-06-09 上海特化医药科技有限公司 Preparation method of 6-substituted amino-3-cyano quinoline compound and midbody thereof
DK3000467T3 (en) 2009-04-06 2023-03-27 Wyeth Llc TREATMENT WITH NERATINIB AGAINST BREAST CANCER
GB0922302D0 (en) * 2009-12-22 2010-02-03 Imp Innovations Ltd Compounds
CN102146084B (en) * 2010-02-04 2014-05-07 江苏恒瑞医药股份有限公司 3-cyan-6-aminoquinoline derivatives, preparation method thereof and application thereof in medicines
AU2012232670A1 (en) 2011-03-23 2013-09-12 Ariel-University Research And Development Company Ltd. Treatment of proliferative disorders with a chemiluminescent agent
CN102718679B (en) * 2011-03-30 2016-06-08 北京万全阳光医药科技有限公司 That preparation method replacing Buddhist nun's key intermediate of a kind of promise
CN102731395B (en) * 2011-04-15 2015-02-04 中国科学院上海药物研究所 Intermediate compound of antitumor drug neratinib and its preparation method and use
EA026353B1 (en) 2012-01-17 2017-03-31 Астеллас Фарма Инк. Pyrazinecarboxamide compound
JP7333313B2 (en) * 2017-09-01 2023-08-24 シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド Nitrogen-containing heterocyclic compounds, methods of preparation, intermediates, compositions and uses
CN110357854A (en) * 2018-03-26 2019-10-22 江苏创诺制药有限公司 A kind of preparation method of linatinib
CN111848581B (en) * 2020-08-19 2021-08-10 昆明学院 Preparation method of 3-cyano-4-anilino-6-aminoquinoline derivative
CN111995618B (en) * 2020-09-02 2021-06-11 重庆医科大学 Preparation method of neratinib impurity G
CN111943933B (en) * 2020-09-02 2021-05-28 重庆医科大学 A kind of preparation method of neratinib impurity D
CN114920695B (en) * 2022-06-29 2023-06-20 深圳大学总医院 A kind of quinazoline derivative and its preparation method, pharmaceutical composition and application

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288082B1 (en) * 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
AR037438A1 (en) * 2001-11-27 2004-11-10 Wyeth Corp 3-CYANOKINOLINES AS INHIBITORS OF EGF-R AND HER2 KINASES, A PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS AND THE USE OF SUCH COMPOUNDS FOR THE MANUFACTURE OF MEDICINES

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005034955A1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104926669A (en) * 2014-03-18 2015-09-23 江苏豪森医药集团连云港宏创医药有限公司 Preparation method of trans-4-dimethylaminocrotonic acid hydrochloride

Also Published As

Publication number Publication date
AU2003304497A1 (en) 2005-04-27
WO2005034955A1 (en) 2005-04-21
UA85394C2 (en) 2009-01-26
BR0318503A (en) 2006-09-12
MXPA06002846A (en) 2006-06-14
AU2003304497B2 (en) 2010-06-24
CA2537978C (en) 2011-08-02
CA2537978A1 (en) 2005-04-21

Similar Documents

Publication Publication Date Title
US7399865B2 (en) Protein tyrosine kinase enzyme inhibitors
CA2537978C (en) Substituted quinolines as protein tyrosine kinase enzyme inhibitors
AU763669B2 (en) Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
EP1163227B1 (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds, and processes for preparing them
KR100862873B1 (en) Bicyclic heterocycle, medicament containing the compound and preparation method thereof
US6288082B1 (en) Substituted 3-cyanoquinolines
KR101540421B1 (en) Spiro substituted compounds as angiogenesis inhibitors
DE69733008T2 (en) CHINAZOLINE DERIVATIVES AS ANTITUM-AGENT
EP1448531B1 (en) 3-cyanoquinolines as inhibitors of egf-r and her2 kinases
CN103664802B (en) As the quinazoline analogs of receptor tyrosine kinase inhibitors
KR20010006047A (en) Substituted 3-cyano quinolines
US20070299092A1 (en) Quinone Substituted Quinazoline and Quinoline Kinase Inhibitors
CN101180273A (en) The method for synthesizing 6-alkylaminoquinoline derivatives
BRPI0318503B1 (en) SUBSTITUTED QUINOLINES AND PHARMACEUTICAL COMPOSITION UNDERSTANDING THE SAME
HK1035188B (en) Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
HU230095B1 (en) Substituted 3-cyanoquinolines with inhibitory activity against protein tyrosine kinases

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060407

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

17Q First examination report despatched

Effective date: 20070305

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070918